Johnson & Johnson (NYSE:JNJ) Shares Up 1.1% - What's Next?

Key Points

• Johnson & Johnson's shares increased by 1.1%, reaching a price of $179.69 after trading as high as $179.91, with a daily volume of about 8.5 million shares.
• Equities analysts have upgraded their ratings for Johnson & Johnson, with price targets now ranging from $185.00 to $206.00, indicating a positive outlook for the stock.
• The company declared a quarterly dividend of $1.30 per share, reflecting an annualized dividend of $5.20 and a yield of 2.9%.

Johnson & Johnson (NYSE:JNJ - Get Free Report) shares were up 1.1% on Friday . The company traded as high as $179.91 and last traded at $179.69. Approximately 8,547,880 shares traded hands during trading, a decline of 4% from the average daily volume of 8,927,817 shares. The stock had previously closed at $177.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on JNJ shares. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $167.00 to $206.00 in a report on Tuesday. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Citigroup lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research report on Friday, September 19th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Trading Up 1.1%

The stock has a market capitalization of $432.75 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 2.25 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company's 50 day moving average is $174.09 and its 200 day moving average is $161.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. W.H. Cornerstone Investments Inc. raised its stake in Johnson & Johnson by 0.7% during the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company's stock worth $1,206,000 after acquiring an additional 58 shares in the last quarter. YANKCOM Partnership grew its holdings in shares of Johnson & Johnson by 0.8% during the second quarter. YANKCOM Partnership now owns 7,042 shares of the company's stock worth $1,076,000 after purchasing an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 3.1% during the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company's stock worth $309,000 after purchasing an additional 60 shares during the last quarter. Ellis Investment Partners LLC grew its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock worth $1,307,000 after purchasing an additional 62 shares during the last quarter. Finally, Cypress Wealth Services LLC grew its holdings in shares of Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock worth $1,013,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.